how long till retatrutide start working Does Take to Work? Most people quit before it

99 Until more robust trials confirm their safety specifically in patients with reduced LVEF, GLP-1 RAs should be used cautiously in this population

While these emerging medications hold promise for advancements in obesity-related healthcare, there is limited knowledge to date on the effectiveness of these drugs among diverse populations, and to what extent these treatments are accessible to groups disproportionately affected by obesity

"We expect all of them to take note of what could be the potential consequences of their continued behavior," John Kuckelman, Novo Nordisk's group general counsel, told USA TODAY

Relatively recent

Additionally, the safety and tolerability profiles of GLP-1RAs have been well-established

MASLD / Liver Research Metabolic dysfunction-associated steatotic liver disease is under Phase 3 evaluation